Understanding MS4A18: A Potential Drug Target and Biomarker (G728588)
Understanding MS4A18: A Potential Drug Target and Biomarker
MS4A18 (M4A18_HUMAN), also known as CD11b, is a protein that is expressed in various tissues of the human body, including the liver, spleen, and peripheral blood cells. It is a member of the integrin alpha-2 (CD11b) subfamily, which is characterized by the presence of a single transmembrane domain and various cytoplasmic interactions.
MS4A18 is involved in many different cellular processes in the body, including inflammation, immune response, and tissue repair. Its expression has been observed in a variety of diseases and conditions, including cancer, autoimmune disorders, and infections.
One of the most promising aspects of MS4A18 is its potential as a drug target. Its involvement in multiple cellular processes makes it an attractive target for small molecules, antibodies, and other therapeutic agents that can modulate its activity and improve treatment outcomes.
One of the key challenges in studying MS4A18 as a drug target is its complex structure and function. The protein is highly conserved and has a relatively small size, which makes it difficult to study its molecular details. Additionally, its expression is often detected in a variety of cell types, which can make it challenging to isolate and study specific forms of the protein.
Despite these challenges, researchers have made significant progress in the study of MS4A18. Initial studies have shown that MS4A18 is involved in various cellular processes, including cell adhesion, migration, and invasion. Its expression has also been associated with various diseases, including cancer, autoimmune disorders, and neurodegenerative diseases.
In addition to its potential as a drug target, MS4A18 also has potential as a biomarker. Its expression has been observed in a variety of diseases and conditions, including cancer, autoimmune disorders, and infections. This makes it a promising tool for the development of new diagnostic tests and therapies.
One of the most promising applications of MS4A18 as a biomarker is its potential to identify new biomarkers for cancer. Its expression has been observed in a variety of cancer types, including breast, lung, and ovarian cancer. This makes it a promising tool for the development of new cancer biomarkers and the improvement of current diagnostic tests.
Another potential application of MS4A18 as a biomarker is its potential to identify new biomarkers for autoimmune disorders. Its expression has been observed in a variety of autoimmune disorders, including rheumatoid arthritis, lupus, and multiple sclerosis. This makes it a promising tool for the development of new autoimmune disorder biomarkers and the improvement of current diagnostic tests.
In addition to its potential as a biomarker, MS4A18 also has potential as a drug target. Its expression has been associated with various diseases, including cancer, autoimmune disorders, and neurodegenerative diseases. This makes it a promising target for small molecules, antibodies, and other therapeutic agents that can modulate its activity and improve treatment outcomes.
Overall, MS4A18 is a protein that has significant potential as a drug target and biomarker. Its structure and function are still being fully understood, but its involvement in multiple cellular processes makes it an attractive target for small molecules, antibodies, and other therapeutic agents. Further research is needed to fully explore its potential as a drug and biomarker.
Protein Name: Membrane Spanning 4-domains A18
The "MS4A18 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MS4A18 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
MS4A2 | MS4A3 | MS4A4A | MS4A4E | MS4A5 | MS4A6A | MS4A6E | MS4A7 | MS4A8 | MSANTD1 | MSANTD2 | MSANTD3 | MSANTD4 | MSC | MSC-AS1 | MSGN1 | MSH2 | MSH3 | MSH4 | MSH5 | MSH5-SAPCD1 | MSH6 | MSI1 | MSI2 | MSL1 | MSL2 | MSL3 | MSL3P1 | MSLN | MSLNL | MSMB | MSMO1 | MSMP | MSN | MSNP1 | MSR1 | MSRA | MSRA-DT | MSRB1 | MSRB1P1 | MSRB2 | MSRB3 | MSRB3-AS1 | MSS51 | MST1 | MST1L | MST1P2 | MST1R | MSTN | MSTO1 | MSTO2P | MSX1 | MSX2 | MSX2P1 | MT1A | MT1B | MT1DP | MT1E | MT1F | MT1G | MT1H | MT1HL1 | MT1IP | MT1JP | MT1L | MT1M | MT1P1 | MT1P3 | MT1X | MT1XP1 | MT2A | MT3 | MT4 | MTA1 | MTA1-DT | MTA2 | MTA3 | MTAP | MTARC1 | MTARC2 | MTATP6P1 | MTATP8P1 | MTBP | MTCH1 | MTCH2 | MTCL1 | MTCO1P1 | MTCO1P12 | MTCO1P15 | MTCO2P33 | MTCO3P1 | MTCO3P12 | MTCP1 | MTDH | MTERF1 | MTERF2 | MTERF3 | MTERF4 | MTF1 | MTF2
